Treatment of hyperproliferative disorders with diarylhydantoin compounds
View Patent ↗The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
1. A method for treating prostate cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the prostate cancer.
2. The method of claim 1 , wherein the compound is administered at a dosage in the range of from about 0.001 mg per kg body weight per day to about 100 mg per kg body weight per day.
3. The method of claim 1 , wherein the compound is administered at a dosage in the range of from about 1 mg per kg body weight per day to about 10 mg per kg body weight per day.
4. The method of claim 1 , wherein the compound is administered at a dosage in the range of from about 0.1 mg per kg body weight per day to about 10 mg per kg body weight per day.
5. The method of claim 1 , wherein the compound is administered at a dosage of about 1 mg per kg body weight per day.
6. The method of claim 1 , wherein the prostate cancer is hormone refractory prostate cancer.
7. The method of claim 1 , wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, topically, or nasally.
8. The method of claim 1 , wherein the compound is administered orally.
9. The method of claim 1 , wherein the compound is administered in a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill.
10. The method of claim 1 , wherein the compound is administered in a form selected from the group consisting of a capsule, tablet, and pill.
11. The method of claim 1 , wherein the prostate cancer is hormone sensitive prostate cancer.
12. The method of claim 1 , wherein the compound is
13. The method of claim 1 , wherein the compound is administered with a pharmaceutically acceptable carrier or diluent.
14. The method of claim 13 , wherein the pharmaceutically acceptable carrier or diluent comprises one or more of dimethylsulfoxide (DMSO), polyethylene glycol (PEG), and water.
15. The method of claim 1 , wherein the compound is administered at a dosage of about 2 mg per kg body weight per day.
16. The method of claim 1 , wherein the compound is administered to achieve a peak plasma concentration in the range of from about 0.5 μM to about 75 μM.
17. The method of claim 1 , wherein the compound is administered to achieve a peak plasma concentration of about 10 μM.
18. The method of claim 1 , wherein the compound is administered to achieve a steady state plasma concentration of from about 5 μM to about 100 μM.
19. The method of claim 1 , wherein the compound is administered to achieve a steady state plasma concentration of from about 10 μM to about 50 μM.
20. The method of claim 1 , wherein the compound is administered to achieve a steady state plasma concentration of about 25 μM.
21. The method of claim 1 , wherein the compound is administered daily.
22. The method of claim 1 , wherein the compound is administered three times per day.
23. The method of claim 1 , wherein the compound is administered in a unit dosage form comprising from about 5 mg to about 1000 mg of active ingredient per unit dosage form.
24. The method of claim 1 , wherein the compound is administered in a unit dosage form comprising about 100 mg of active ingredient per unit dosage form.
25. A method for treating benign prostate hyperplasia comprising administering a therapeutically effective amount of a compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the benign prostate hyperplasia.
26. The method of claim 1 , wherein the compound is
27. The method of claim 1 , wherein the compound is
28. The method of claim 25 , wherein the compound is
29. The method of claim 25 , wherein the compound is
30. The method of claim 25 , wherein the compound is
31. The method of claim 12 , wherein the prostate cancer is hormone refractory prostate cancer.
32. The method of claim 12 , wherein the prostate cancer is hormone sensitive prostate cancer.
33. A method for treating breast cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the breast cancer.
34. The method of claim 33 , wherein the compound is
35. The method of claim 33 , wherein the compound is
36. The method of claim 33 , wherein the compound is
37. A method for treating ovarian cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the ovarian cancer.
38. The method of claim 37 , wherein the compound is
39. The method of claim 37 , wherein the compound is
40. The method of claim 37 , wherein the compound is